Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotech company, announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference scheduled for June 16-17, 2025. CEO Wa'el Hashad will deliver a pre-recorded corporate presentation, which will be available on-demand starting Monday, June 16, at 7:00 a.m. ET. The presentation can be accessed through the company's website under the 'Events and Presentations' section, with the replay remaining available for 90 days following the conference. Longeveron focuses on developing cellular therapies for life-threatening and chronic aging-related conditions.
Longeveron (NASDAQ: LGVN), un'azienda biotecnologica specializzata in medicina rigenerativa in fase clinica, ha annunciato la sua partecipazione alla 6ª Conferenza Annuale Ibrida Neuro Perspectives di H.C. Wainwright, prevista per il 16-17 giugno 2025. Il CEO Wa'el Hashad presenterà una presentazione aziendale preregistrata, disponibile on-demand a partire da lunedì 16 giugno alle 7:00 ET. La presentazione sarà accessibile tramite il sito web dell'azienda nella sezione 'Eventi e Presentazioni', con la possibilità di rivederla per 90 giorni dopo la conferenza. Longeveron si concentra sullo sviluppo di terapie cellulari per condizioni gravi e croniche legate all'invecchiamento.
Longeveron (NASDAQ: LGVN), una empresa biotecnológica en etapa clínica especializada en medicina regenerativa, anunció su participación en la 6ª Conferencia Anual Híbrida Neuro Perspectives de H.C. Wainwright, programada para los días 16 y 17 de junio de 2025. El CEO Wa'el Hashad ofrecerá una presentación corporativa pregrabada, disponible bajo demanda a partir del lunes 16 de junio a las 7:00 a.m. ET. La presentación podrá accederse a través del sitio web de la compañía en la sección 'Eventos y Presentaciones', y la repetición estará disponible durante 90 días después de la conferencia. Longeveron se enfoca en desarrollar terapias celulares para condiciones graves y crónicas relacionadas con el envejecimiento.
임상 단계 재생 의학 바이오테크 기업인 Longeveron(NASDAQ: LGVN)은 2025년 6월 16일부터 17일까지 예정된 H.C. Wainwright 제6회 연례 Neuro Perspectives 하이브리드 컨퍼런스에 참여한다고 발표했습니다. CEO Wa'el Hashad는 사전 녹화된 기업 발표를 진행하며, 이는 6월 16일 월요일 오전 7시(동부 시간)부터 온디맨드로 제공됩니다. 발표는 회사 웹사이트의 '이벤트 및 발표' 섹션에서 확인할 수 있으며, 컨퍼런스 후 90일간 다시보기 가능합니다. Longeveron은 생명을 위협하는 만성 노화 관련 질환을 위한 세포 치료제 개발에 주력하고 있습니다.
Longeveron (NASDAQ : LGVN), une société biotechnologique en phase clinique spécialisée en médecine régénérative, a annoncé sa participation à la 6e conférence annuelle hybride Neuro Perspectives de H.C. Wainwright, prévue les 16 et 17 juin 2025. Le PDG Wa'el Hashad présentera une présentation d'entreprise préenregistrée, disponible en replay à partir du lundi 16 juin à 7h00 ET. La présentation sera accessible via le site web de la société dans la section « Événements et Présentations », avec une disponibilité du replay pendant 90 jours après la conférence. Longeveron se concentre sur le développement de thérapies cellulaires pour des pathologies graves et chroniques liées au vieillissement.
Longeveron (NASDAQ: LGVN), ein biotechnologisches Unternehmen im klinischen Stadium der regenerativen Medizin, gab seine Teilnahme an der 6. jährlichen hybriden Neuro Perspectives-Konferenz von H.C. Wainwright bekannt, die für den 16. bis 17. Juni 2025 geplant ist. CEO Wa'el Hashad wird eine vorab aufgezeichnete Unternehmenspräsentation halten, die ab Montag, dem 16. Juni, um 7:00 Uhr ET auf Abruf verfügbar sein wird. Die Präsentation kann über die Unternehmenswebseite im Bereich 'Events und Präsentationen' abgerufen werden, wobei die Wiedergabe für 90 Tage nach der Konferenz verfügbar bleibt. Longeveron konzentriert sich auf die Entwicklung von Zelltherapien für lebensbedrohliche und chronische altersbedingte Erkrankungen.
Positive
None.
Negative
None.
MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa’el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.
Details for the Company’s corporate presentation:
Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ET
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 90 days following the conference.
About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact: Derek Cole Investor Relations Advisory Solutions derek.cole@iradvisory.com
FAQ
When is Longeveron (LGVN) presenting at the H.C. Wainwright Neuro Conference 2025?
Longeveron's pre-recorded presentation will be available on-demand starting Monday, June 16, 2025, at 7:00 a.m. ET.
Who will be presenting for Longeveron (LGVN) at the H.C. Wainwright conference?
Wa'el Hashad, CEO of Longeveron, will deliver the corporate presentation.
How long will Longeveron's (LGVN) presentation replay be available?
The webcast replay will be available on Longeveron's website for 90 days following the conference.
What type of company is Longeveron (LGVN)?
Longeveron is a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
